Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Capecitabine After Induction FOLFRINOX in Metastatic Pancreatic Cancer
NCT05566743Phase 2Unknown
- Sponsor
- Menoufia University
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in pancreatic adenocarcinoma (PDAC), sponsored by Menoufia University. Status: unknown.
02
Drugs
capecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05566743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566743.